tiprankstipranks
Trending News
More News >
Organogenesis Holdings (ORGO)
:ORGO

Organogenesis Holdings (ORGO) AI Stock Analysis

Compare
450 Followers

Top Page

OR

Organogenesis Holdings

(NASDAQ:ORGO)

Rating:56Neutral
Price Target:
$4.00
▼(-1.23%Downside)
Organogenesis Holdings has notable financial challenges, including declining revenue and profitability, heavily impacting its overall score. Short-term technical indicators suggest some bullish momentum, but valuation concerns due to unprofitability and the lack of dividend yield weigh on the stock. The earnings call provides some hope with reaffirmed guidance and strategic initiatives, but significant operational and market challenges remain.
Positive Factors
Financial Stability
The recent debt reduction by Organogenesis Holdings has contributed to a higher price target, reflecting improved financial stability.
Product Demand
Revenue in the fourth quarter exceeded expectations with a strong sales performance, indicating robust demand for Organogenesis's products.
Negative Factors
Guidance and Sales Risk
Management's revised sales guidance implies a significant back-end weighted ramp, which adds a degree of risk in hitting full year targets.
LCD Uncertainty
ORGO's 1Q25 results were negatively impacted by continued LCD uncertainty regarding skin substitute grafts, where implementation has been delayed a third time to January 1, 2026.

Organogenesis Holdings (ORGO) vs. SPDR S&P 500 ETF (SPY)

Organogenesis Holdings Business Overview & Revenue Model

Company DescriptionOrganogenesis Holdings Inc. (ORGO) is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of products for the advanced wound care and surgical biologics markets. The company operates primarily in the healthcare sector, specializing in regenerative medicine solutions that aim to improve patient outcomes through innovative technologies. Organogenesis offers a comprehensive portfolio of products that address the needs of patients and healthcare providers in both the acute and chronic wound care segments, as well as surgical and sports medicine applications.
How the Company Makes MoneyOrganogenesis Holdings Inc. generates revenue primarily through the sale of its advanced wound care and surgical biologics products. The company's revenue streams are largely driven by the commercialization of its proprietary technologies, which include bioactive wound healing and tissue repair solutions. Organogenesis partners with healthcare providers, hospitals, and clinics to provide these products for patient care, establishing contracts and agreements that facilitate widespread distribution. Additionally, the company invests in research and development to expand its product offerings and enhance its competitive position in the regenerative medicine market. Significant factors contributing to its earnings include a growing demand for effective wound care solutions and strategic partnerships that enhance product reach and adoption.

Organogenesis Holdings Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: -24.16%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a challenging quarter for Organogenesis, marked by significant revenue declines and increased losses due to disruptions from LCD implementation delays. However, the reaffirmed revenue guidance, growth in Surgical and Sports Medicine, and strategic advancements in product development and manufacturing highlight potential for future recovery and growth.
Q1-2025 Updates
Positive Updates
Surgical and Sports Medicine Revenue Growth
Net revenue from Surgical and Sports Medicine products for the first quarter was $6.8 million, up 11% year-over-year.
Strong Financial Position
The company had $110.5 million in cash, cash equivalents, and restricted cash with no outstanding debt obligations as of 03/31/2025.
Reaffirmed 2025 Revenue Guidance
The company reaffirmed its net revenue guidance for 2025 of between $480 million and $535 million, representing a year-over-year change in the range of roughly flat to an increase of 11%.
Development and Submission Progress
Organogenesis is on track to submit additional clinical and real-world evidence to CMS and plans to submit a BLA for RENEW by the end of the year.
Expansion of Manufacturing Capabilities
Significant progress in expanding manufacturing capabilities with a new facility in Smithfield, Rhode Island, to support new product introductions and reintroductions.
Negative Updates
Significant Revenue Decline
Net revenue for the first quarter was $86.7 million, down 21% year-over-year.
Advanced Wound Care Revenue Decline
Advanced Wound Care net revenue for the first quarter was $79.9 million, down 23% year-over-year.
Increased Operating Loss
Operating loss for the first quarter was $26.7 million compared to an operating loss of $3.9 million last year, an increase of $22.9 million.
Net Loss Increase
GAAP net loss for the first quarter was $18.8 million compared to a net loss of $2.1 million last year, an increase of $16.7 million.
Challenges Due to LCD Implementation Delays
Delays in LCD implementation led to uncertainty and disruption in customer demand and ordering patterns, impacting revenue and gross profit.
Company Guidance
During the first quarter 2025 earnings call, Organogenesis Holdings Inc. reaffirmed their financial guidance for the year, projecting net revenue between $480 million and $535 million, with anticipated growth ranging from flat to an 11% increase year-over-year. The company reported a Q1 net revenue of $86.7 million, reflecting a 21% decline, aligning with their prior guidance of $85 to $95 million. Advanced Wound Care products contributed $79.9 million, a 23% decrease, while Surgical and Sports Medicine products reported an 11% increase, totaling $6.8 million. The gross margin for the quarter was 72.6%, slightly down from last year's 73.9%, impacted by lower revenue and product expiration due to a delayed LCD implementation. Operating expenses increased by 5% to $89.7 million, influenced by a $6.6 million asset write-down, partially offset by a 17% reduction in R&D expenses. The call highlighted the company's strategic focus on leveraging its diverse product portfolio and customer relationships to navigate market challenges, particularly in light of CMS's delay in LCD implementation to 2026, which Organogenesis supports as an opportunity to review coverage policies and submit additional evidence for product coverage.

Organogenesis Holdings Financial Statement Overview

Summary
Organogenesis Holdings shows a mix of strengths and weaknesses in its financial performance. While the company maintains a strong gross profit margin and a low debt-to-equity ratio, it faces challenges with declining revenue, profitability, and negative cash flow. The declining equity and liquidity issues further highlight operational inefficiencies that need addressing.
Income Statement
45
Neutral
Organogenesis Holdings experienced a decline in revenue with a negative growth rate of around -4.82% from 2024 to TTM (Trailing-Twelve-Months), alongside a consistent downward trajectory since 2021. The company shows negative net profit margins and EBIT margins in the TTM, indicating operational challenges. However, gross profit margins remain strong at 74.89% in TTM, suggesting efficient cost management. Despite strong historical performance, recent declines highlight potential risks.
Balance Sheet
55
Neutral
The balance sheet reflects moderate stability with a debt-to-equity ratio of 0.18 in TTM, showcasing low leverage and prudent financial management. The equity ratio stands at 51.96%, indicating a healthy proportion of equity within the asset structure. However, declining stockholders' equity and rising liabilities over the periods pose risks to financial stability. The return on equity is negative in TTM, further pointing to profitability issues.
Cash Flow
40
Negative
The cash flow analysis reveals challenges with negative free cash flow in TTM, deteriorating from previous periods, indicating liquidity issues. The operating cash flow to net income ratio is 0.24, highlighting operational inefficiencies. While past periods showed positive free cash flow, recent figures suggest potential cash constraints, necessitating careful liquidity management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue458.76M482.04M433.14M450.89M468.06M338.30M
Gross Profit343.58M366.30M326.66M345.87M353.86M250.98M
EBITDA-15.55M15.76M36.03M40.32M87.00M37.23M
Net Income-18.63M861.00K4.95M15.53M94.20M17.23M
Balance Sheet
Total Assets467.39M497.89M460.02M449.36M443.26M294.49M
Cash, Cash Equivalents and Short-Term Investments109.97M135.57M104.34M102.48M113.93M84.39M
Total Debt42.63M43.31M119.35M123.79M132.30M84.77M
Total Liabilities99.33M112.57M181.36M183.69M201.22M148.41M
Stockholders Equity242.90M385.32M278.66M265.67M242.03M146.08M
Cash Flow
Free Cash Flow-7.00M4.18M6.55M-9.04M30.76M-14.34M
Operating Cash Flow4.43M14.21M30.92M24.86M61.98M6.80M
Investing Cash Flow-11.44M-10.03M-24.36M-33.90M-31.22M-24.83M
Financing Cash Flow28.19M27.64M-5.50M-2.20M-1.04M42.47M

Organogenesis Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.05
Price Trends
50DMA
3.63
Positive
100DMA
4.00
Positive
200DMA
3.65
Positive
Market Momentum
MACD
0.11
Negative
RSI
68.17
Neutral
STOCH
89.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Positive. The current price of 4.05 is above the 20-day moving average (MA) of 3.36, above the 50-day MA of 3.63, and above the 200-day MA of 3.65, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 68.17 is Neutral, neither overbought nor oversold. The STOCH value of 89.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORGO.

Organogenesis Holdings Risk Analysis

Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Organogenesis Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$973.91M24.9719.23%17.17%-51.97%
68
Neutral
$1.08B34.0611.86%1.80%19.12%141.45%
63
Neutral
$853.63M-34.65%252.64%85.10%
60
Neutral
$1.13B-37.23%53.49%33.18%
56
Neutral
$479.51M928.57-4.92%5.35%-432.51%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
44
Neutral
$593.18M-949.46%25.38%15.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ORGO
Organogenesis Holdings
4.05
1.27
45.68%
AVDL
Avadel Pharmaceuticals
8.81
-5.97
-40.39%
PAHC
Phibro Animal Health
27.94
11.44
69.33%
COLL
Collegium Pharmaceutical
30.51
-1.67
-5.19%
HROW
Harrow Health
30.57
8.45
38.20%
EOLS
Evolus
9.21
-1.72
-15.74%

Organogenesis Holdings Corporate Events

Executive/Board ChangesShareholder Meetings
Organogenesis Holdings Approves Key Proposals at Annual Meeting
Neutral
Jun 24, 2025

On June 23, 2025, Organogenesis Holdings held its Annual Meeting of Stockholders where several key proposals were voted on and approved. The meeting included the re-election of Garrett Lustig to the board of directors and the election of other directors to serve until the next annual meeting. Additionally, stockholders approved the compensation for named executive officers and the issuance of over 20% of Class A common stock upon conversion of Series A Convertible Preferred Stock, which may be deemed a change of control under Nasdaq rules. The appointment of RSM US LLP as the independent registered public accounting firm for 2025 was also ratified.

The most recent analyst rating on (ORGO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025